The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Novartis' 2013 sales performance.
Other Gold winners were Alliance Pharma, Bayer, CALM, Haleon, Kite Pharma, a Gilead Company, Kyowa Kirin, LEO Pharma, the RCN Foundation, Novartis, Santen, Takeda UK and UCB.
The list includes Bristol Myers Squibb and Pfizer’s Eliquis (apixaban), Novartis' Entresto (valsartan/sacubitril), Amgen's Enbrel (etanercept), AstraZeneca's Farxiga (dapagliflozin), Merck &Co's Januvia (sitagliptin), Eli Lilly and
Sandoz, a Novartis division, has announced that its biosimilar Tyruko (natalizumab-sztn) has been approved by the US Food and Drug Administration (FDA) to treat adults with relapsing forms of multiple
According to data from a pre-specified interim analysis of the study, Welireg showed a statistically significant and clinically meaningful improvement in progression-free survival compared to Novartis’ Afinitor (everolimus).
Novartis has shared positive top-line results from two late-stage studies evaluating its Bruton’s tyrosine kinase (BTK) inhibitor, remibrutinib, in patients with chronic spontaneous urticaria (CSU) whose symptoms are ... Novartis’ remibrutinib works
No results were found
Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...